Abstract: The present invention provides multispecific antibodies comprising a Fab region and an Fc region, wherein the Fab region comprises a binding site specific for an epitope of the variable delta 1 (V?1) chain of a ?? T cell receptor (TCR); and the Fc region comprises an EGFR binding site. The present invention also provides compositions and pharmaceutical compositions comprising such multispecific antibodies, and method of making such multispecific antibodies. The present invention also provides methods of treatment and medical uses involving the multispecific antibodies.

Abstract: The present invention provides multispecific antibodies comprising a Fab region and an Fc region, wherein the Fab region comprises a binding site specific for an epitope of the variable delta 1 (V?1) chain of a ?? T cell receptor (TCR); and the Fe region comprises an EGFR binding site. The present invention also provides compositions and pharmaceutical compositions comprising such multispecific antibodies, and method of making such multispecific antibodies. The present invention also provides methods of treatment and medical uses involving the multispecific antibodies.

Abstract: The present invention provides methods of expanding ?? T cells from a non-haematopoietic tissue source. Further provided are compositions of expanded ?? T cells and methods of using the expanded ?? T cells (e.g., a part of an adoptive T cell therapy).

Abstract: The present invention provides methods of expanding ?? T cells from a non-haematopoietic tissue source. Further provided are compositions of expanded ?? T cells and methods of using the expanded ?? T cells (e.g., apart of an adoptive T cell therapy).

Abstract: The present invention provides high-affinity anti-TCR delta variable 1 (anti-V?1) antibodies and antibody fragments thereof. The present invention also provides compositions and pharmaceutical compositions comprising such antibodies, and method of making such antibodies. The present invention also provides methods of treatment and medical uses involving the antibodies.

Abstract: The invention relates to anti-V?1 antibodies or fragments thereof for use in methods of treating a cancer, an infectious disease or an inflammatory disease in a subject in need thereof.

Abstract: The present invention provides methods of expanding ?? T cells from a non-haematopoietic tissue source. Further provided are compositions of expanded ?? T cells and methods of using the expanded ?? T cells (e.g., apart of an adoptive T cell therapy).

Abstract: The present invention is directed to a nucleic acid molecule comprising a polynucleotide sequence encoding a chimeric antigen receptor comprising (a) an anti-CLEC14A binding domain, (b) a transmembrane domain and (c) an intracellular signalling domain; wherein said anti-CLEC14A binding domain is capable of binding to the C-type lectin domain of CLEC14A. The invention further provides a chimeric antigen receptor encoded by the nucleic acid molecule, a vector comprising the nucleic acid molecule, a cell comprising the nucleic acid molecule, vector or CAR and the therapeutic use of the nucleic acid, vector or cell, particularly in treating CLEC14A expressing conditions.